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ABSTRACT 
Objective: To assess lung function longitudinally after neonatal ECMO, and to identify any effects of 
diagnosis and perinatal characteristics. 
Patients and methods: 121 neonatal ECMO-treated children (70 meconium aspiration syndrome, 20 
congenital diaphragmatic hernia, 31 other diagnoses) performed altogether 191 lung function 
measurements at 5, 8 and/or 12 years. We assessed dynamic and static lung volumes, reversibility of 
airway obstruction and diffusion capacity.  
Results: Mean SDS FEV1 at 5 years before and after bronchodilation (-0.51 and 0.07) was significantly 
higher than at 8 (-0.79 and -0.4, p<0.04) and 12 years (-1.10 and -0.52, p<0.003). Mean SDS for all 
spirometric parameters before and after bronchodilation were significantly lower in the congenital 
diaphragmatic hernia group compared the other diagnostic groups (all p≤0.025). A significant volume 
of trapped air was observed in 86% patients with congenital diaphragmatic hernia, 50% with 
meconium aspiration syndrome and 58% with other diagnoses. After bronchodilation mean SDS FEV1 
and FVC were negatively influenced by duration of ventilation (both p<0.001) and duration of ECMO 
(p=0.003 and p=0.02 respectively). 
Conclusion: Long-term pulmonary sequelae after neonatal ECMO-treatment mainly occur in 
congenital diaphragmatic hernia patients and tend to deteriorate over time. 
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INTRODUCTION 
Extracorporeal membrane oxygenation (ECMO) is a cardiopulmonary bypass technique providing life 
support when conventional treatment for severe respiratory failure is not enough. Underlying 
diagnoses include meconium aspiration syndrome, congenital diaphragmatic hernia (CDH), persistent 
pulmonary hypertension of the newborn (PPHN), sepsis and pneumonia. Ventilator settings are low 
during ECMO so the lungs can rest. Lung healing is promoted  by reducing barotrauma and hyperoxia 
[1]. The collaborative UK ECMO trial showed improved survival of term infants with severe respiratory 
failure who were treated with ECMO [2-5]. The long-term pulmonary sequelae of neonatal ECMO have 
hardly been studied. Cross-sectional studies during or shortly after ECMO all reported reduced lung 
function, perhaps due to severity of the underlying respiratory disease [6-10]. 
We report a study in which we longitudinally evaluated residual lung function in neonatal ECMO-
treated children now between 5 and 12 years of age, distinguished by underlying diagnosis. 
Furthermore we related perinatal characteristics to lung function.  
 
METHODS 
 
Participants 
A prospective longitudinal follow-up study was conducted in children who received veno-arterial (VA) 
ECMO support within the first week of life between February 1991 and August 2004 at the Intensive 
Care Unit of the Erasmus MC-Sophia Children's Hospital. The cohort was supplemented with 5 
children who received VA ECMO in two other ECMO centers (Nijmegen, The Netherlands: n=4 and 
Leuven, Belgium: n=1). Inclusion criteria and treatment protocols in those centers were the same as 
ours. ECMO was initiated in case of reversible severe respiratory failure and an estimated mortality 
risk of higher than 80% using the entry criteria of Stolar et al [11]. We reported our Eentry criteria and 
exclusion criteria earlier [10] and these did not change during the study period. The study was 
embedded in a structured prospective post-ECMO follow-up program initiated in 2001 that provides for 
regular assessments of lung function, growth and developmental parameters until 18 years of age 
[12]. Based on the national consensus on neonatal follow-up and the Dutch Ministry of Health’s 
requirement to provide relevant data, the assessment protocol is the standard of care in the 
Netherlands following ECMO. As a consequence IRB approval was waived. The parents received 
information about the study and gave written informed consent for analysis of data collected during 
routine care. Background data were obtained from the charts, including diagnosis, gestational age, 
birth weight, age at onset of ECMO, duration of ECMO support, duration of mechanical ventilation, 
highest mean airway pressure (MAP) and highest oxygenation index (OI) prior to ECMO, total duration 
of mechanical ventilation (including ECMO), and duration of oxygen dependency.    
Following Jobe and Bancalari, we defined chronic lung disease (CLD) as oxygen dependency at day 28 and 
classified it as as mild, moderate or severe, based on the amount of oxygen needed at day 56 or at discharge, 
whichever comes first [13].   
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Lung function 
Pulmonary function tests were performed at 5, 8, and 12 years if children were in a clinically stable 
condition. 
We obtained flow-volume curves; forced expiratory volume in 1 sec (FEV1), forced vital capacity 
(FVC), and maximum midexpiratory phase (FEF25-75) were determined from the best of three 
reproducible maneuvers. At 8 and 12 years we also determined total lung volume, functional residual 
capacity, and residual volume by helium dilution spirometry (TLCspiro , FRCspiro and RVspiro, 
respectively) and by bodyplethysmography (TLCpleth, FRCpleth and RVpleth), and carbon monoxide 
diffusion capacity (DLCO) corrected for alveolar volume (KCO) using a single breath method (all 
equipment: Jaeger Masterlab, Viasys, Hoechberg, Germany). Equipment and procedures were all 
according to European Respiratory Society (ERS) criteria [14].  
 
 
Respiratory morbidity 
At 5, 8, and 12 years a medical history was taken including the presence of atopic and respiratory 
symptoms, and prescription of prophylactic antibiotics, bronchodilators and inhaled corticosteroids 
medication for pulmonary disease.  
 
Analysis 
The OI was calculated as: [(Mean airway pressure x FiO2)/PaO2] x 100 [11]. FEV1, FVC, FEV1/FVC, 
and FEF25-75  were expressed as SDS calculated from the reference values of Stanojevic [15]. Volume 
of trapped air is considered significant when the ratio of plethysmographic to spirometric FRC is larger 
than 1.10 [16]. Post bronchodilator changes of FEV1 were calculated as a simple percentage of the 
prebronchodilator value: 100x (post-pre)/post. A >11% bronchodilator change in FEV1 was considered 
significant, reflecting reversible airflow obstruction [17].  
The null hypothesis that the SDS of lung function parameters did not differ from those of the reference 
population (SDS=0) was tested with the one sample Student’s T-test. 
Mixed-model ANOVA, which allows for missing data, was applied for the longitudinal evaluation of the 
spirometric SDS at 5, 8 and 12 years and RV/TLC ratios, and the ratio of FRCpleth to FRCspiro and SDS 
of DLCO at 8 and 12 years [18]. 
Values for the two largest diagnostic subgroups (CDH and MAS) were analyzed separately. The other 
subgroups were but small and  we grouped these as “other diagnoses”. Correlation coefficients 
between lung function parameters and gestational age, birth weight and duration of ventilation, 
supplemental oxygen and ECMO were established with Spearman‘s correlation test. 
Possible associations between lung function parameters and CLD were explored by univariate 
analyses. All results are expressed as mean (SD) or median. P-values of <0.05 were considered 
significant. Statistical analysis was performed using SPSS 17.0. 
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RESULTS 
238 children received ECMO support within the first week of life between February 1991 and August 
2004 in the Erasmus MC - Sophia Children’s Hospital; 166 survived (70%) (Figure 1). Twenty children 
could not perform reproducible lung function tests. Five children could not be traced, 4 were followed 
in another ECMO center, parents of 15 children gave no consent, and 6 children had not been tested 
for logistic reasons. Hence, the study population included 121 ECMO survivors (including the 
aforementioned 5 from other centers) who altogether performed 191 pulmonary function tests between 
February 2002 and March 2011 in Erasmus MC Rotterdam. Seventy children (58%) had been 
diagnosed with MAS; 20 (17%) with CDH. Smaller subgroups received ECMO for: persistent 
pulmonary hypertension of the newborn (PPHN; n=17), sepsis (n=8), pneumonia (n=4) and cardio 
respiratory failure (n=2). The characteristics at birth are shown in Table 1. The tested children  did not 
differ from the non-tested children in gestational age, birth weight, underlying diagnosis, highest MAP, 
highest OI, age at onset of ECMO or duration of ECMO (data not shown). Atopic symptoms were 
reported in 7 (9.7%), 9 (11.7%) and 9 (21.4%) children at 5, 8 and 12 years respectively. One child at 
age 5 (1.4%) and 1 child at age 8 years (1.3%) took antibiotic prophylaxis to prevent recurrent airway 
infections. At 5 years, 10 children (13.9%) used bronchodilators (4 with additional inhaled steroids). At 
8 years, 8 children (10.4%) used bronchodilators (5 with additional inhaled steroids). At 12 years, 4 
children (9.8%) used bronchodilators (2 with additional inhaled steroids). 
 
Lung function 
Spirometry 
The results of spirometry after bronchodilation (BD) are shown in Table 2. Significant differences from 
the norm (SDS=0) are indicated in the table. Significant reversibility of FEV1 was observed in 34 
measurements (18%). The median change in FEV1 after BD was 5% (IQR 1 to 10%).  
Mean SDS FEV1 before and after BD significantly changed within time: at 5 years it was significantly 
higher than at 8 years (p=0.039 before and p=0.001 after BD) and at 12 years (p=0.003 before and 
p=0.001 after BD). It did not significantly change between 8 and 12 years.  
Mean SDS FVC before and after BD did not change significantly within time (p-values not shown).  
Mean SDS FEV1/FVC at 5 years was higher than at 8 and 12 years, both before and after BD (all p-
values < 0.001). After BD mean SDS FEV1/FVC did not change significantly between 8 and 12 years; 
before BD it was higher at 8 years (p=0.033).  
Mean SDS FEF25-75  after BD was higher at 5 years than at 8 years (p=0.02); it did not change 
significantly before BD or from 8 to 12 years before and after BD. 
Figures 2 and 3 show the SDS FEV1 at 5, 8, and 12 years for the three subgroups and the whole 
group, before and after BD. Initial diagnosis was a significant determinant in the mixed model: all 
spirometric parameters before BD in the CDH group were significantly lower than those in the other 
two subgroups. The parameters did not significantly differ between the MAS group and the other 
diagnoses group (data not shown). Individual measurements of FEV1, before and after BD, in CDH 
patients are shown in Figures 3 and 4.  
We analysed spirometric values in children with repeated measurements separately. After bronchodilation, 
SDS FEV1 was significantly higher at 5 year compared with 8 and 12 years (p=0.002 and p=0.005 
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respectively). FEV1/FVC was significantly higher at 5 years compared with 8 and 12 years (both p<0.001). 
FEF25-75  was significantly higher at 5 years compared with 8 years (p=0.028), there was no significant 
difference with 12 years. This is similar to the analysis of the whole group, including children with only one 
measurement. For all lung function parameters, differences between the different subgroups were 
independent of age.  
 
Helium dilution spirometry, bodyplethysmography, and diffusion capacity at 8 and 12 years.  
The mean (SD) RV%TLCspiro at 8 years was 22.1 (8.3); at 12 years it was 21.1 (7.0). The mean (SD) 
RV%TLCpleth  at 8 years was 29.4 (8.2); at 12 years it was 26.5 (6.8) (Table 3).  
The mean FRCpleth/spiro was 1.22 (0.22) at 8 years and 1.09 (0.11) at 12 years. A significant volume 
trapped air (defined as FRCpleth/spiro>1.10)[16] was observed in 32 (64%) and 13 (46%) of children at 8 
and 12 years, respectively. This concerned 12/14 measurements in the CDH group (86%), 26/52 in 
the MAS group (50%), and 7/12 in the other diagnoses group (58%).   
Total diffusion capacity did not differ from the norm population at 8 and 12 years (p=0.286 and 
p=0.392 respectively). However, after correction for alveolar volume the diffusion capacity was 
significantly below the norm at the age of 8 (p<0.001) but not at 12 years (p=0.172). 
 
Other determinants of lung function parameters 
Beside the effects of age and initial diagnosis we evaluated the influence of other determinants on 
spirometric parameters. Before BD, mean SDS FEV1 and SDS FVC were negatively influenced by 
duration of ventilation (both parameters p<0.001), duration of ECMO support (p≤0.001 for both 
parameters), and the presence of CLD (both p≤0.001). Both parameters were positively correlated to 
birth weight (both p≤0.001); SDS FEV1 only was positively correlated to gestational age (p=0.001). 
After BD, mean SDS FEV1, SDS FVC and SDS FEF25-75  were negatively influenced by duration of 
ventilation (all parameters p<0.001), duration of ECMO support (all p<0.03), and the presence of CLD 
(all p≤0.001). Mean SDS FEV1, SDS FVC, SDS FEV1/FVC and SDS FEF25-75  were positively 
influenced by birth weight (all p<0.05); mean SDS FEV1 and SDS FEF25-75  were also positively 
influenced by gestational age (both p<0.01). In univariate analysis doubling of the logarithm ventilation 
time resulted in a mean decrease of -0.415 SDS FEV1 at 5 years, -0.782 SDS FEV1 at 8 years, and  
-1.35 SDS FEV1 at 12 years (all p≤0.001). 
RV%TLCpleth and FRCpleth/spiro were positively correlated to duration of ventilation (p<0.001), duration of 
ECMO support (p<0.02), and birth weight (p<0.04). Highest MAP and OI before ECMO did not 
correlate with any of the lung function parameters.  
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DISCUSSION 
Residual lung function of the studied 121 children – in terms of mean SDS FEV1 and SDS FEF25-75 
before BD – had significantly decreased between 5 and 12 years of age. CDH was associated with 
significantly lower spirometric values and higher frequency of a significant volume of trapped air 
compared to other diagnoses. Mean SDS FEV1,FVC, and FEF25-75 were negatively influenced by 
duration of ventilation, and the presence of CLD.  
Long-term pulmonary function abnormalities such as hyperinflation and airway obstruction are well 
recognized after neonatal respiratory failure secondary to lung injury from MAS, CDH and neonatal 
pneumonia [10, 19-20]. Treatment modalities such as supplemental oxygen and mechanical 
ventilation contribute to the pathogenesis of CLD [21]. Avoiding continued exposure to high inspired 
oxygen concentration and barotrauma during the course of ECMO has reduced mortality and 
encouraged lung healing and recovery. To our knowledge this is the first longitudinal study on the 
impact of neonatal ECMO on lung function in children between 5 and 12 years of age.  
Beardsmore et al. in 2000 cross-sectionally studied 51 ECMO patients at age 1 year and found few 
differences in lung function compared with conventionally ventilated controls. This provided 
reassurance that in addition to decreased mortality respiratory function following ECMO was no worse 
[6]. In addition, another study by Beardsmore et al. showed that when children were categorized 
according to the underlying reason for ECMO, those treated for RDS and those treated beyond the 
first 3 weeks for bronchiolitis or pneumonia had poorer pulmonary function 12 months later. However, 
only few CDH patients were included in this studied population of 106 subjects [22]. Hofhuis and 
colleagues found below-average but normal lung volumes and stable forced expiratory flows during 
the first year of life in 64 infants following ECMO. At 12 months, only the CDH patients showed signs 
of hyperinflation with plethysmographic FRC significantly above normal [10]. In an earlier study we 
found significantly impaired expiratory flows and increased FRC levels in 12 ECMO and 31 non-
ECMO treated CDH patients during the first year of life. The ECMO-treated CDH patients had 
significantly higher FRC levels, thus reflecting more hyperinflation [20]. In a cross-sectional study in 54 
eight-year-old patients after severe neonatal respiratory failure, Majaesic and coworkers found a 
poorer pulmonary outcome in the subgroup of ECMO treated CDH patients [23]. In 2004 Hamutcu and 
coworkers cross-sectionally studied 50 children after neonatal ECMO treatment. At a mean age of 11 
years they had significantly lower FEV1 and FEF25-75 and hyperinflation with higher RV compared to 
healthy matched controls. Single breath diffusion capacity for carbon monoxide was within the normal 
range [19]. When children with congenital heart disease (8%) and CDH (12%) were excluded from 
analysis, no significant differences in lung function were observed. Boykin and coworkers reported 
signs of air trapping and mild lower airway obstruction in 17 ECMO-treated MAS patients [7]. 
The strength of the present study is the longitudinal aspect, as most other studies were performed cross-
sectionally. A potential weakness is the lack of appropriate reference values for longitudinal spirometric 
measurements and the lack of a healthy control group in our study. Up-to-date reference data are 
needed to reflect evolving measurement techniques and equipment and changes in population 
characteristics. In 2008, Quanjer and co-workers compared 5 commonly used reference equation sets to 
serial measurements and found that Stanojevic’s equations performed best and are suitable for longitudinal 
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data analysis as they cover a wide age range and account for a gradual transition from childhood into 
adulthood. In another study they compared 30 spirometry datasets and concluded that the use of local 
controls to validate reference equations will rarely be practical due to the numbers required and that the use 
of reference equations derived from large or collected datasets is recommended [24]. Therefore we 
computed SDS of spirometric values using those equations, which distinguish between the effects of 
disease and those of growth and development [25]. As treatment protocols improve over time, results 
from earlier studies may not just be applicable to patients treated with ECMO today. This is, albeit to a lower 
extent, also a limitation of our study. Not all patients were tested at all 3 time points, which created an 
unfavorable but unavoidable heterogeneity in the age distribution. Our ventilation strategies and ECMO 
treatment protocols have indeed been adjusted over the past decade, resulting in better survival in CDH 
patients [26]. Recent protocols based on meta-analysis of retrospective studies provide guidelines for the 
use of ECMO in CDH patients [27]. These could well lead to better long-term pulmonary outcome and lung 
function.  
In our study, the SDS for all spirometric parameters in the CDH group were significantly lower than 
those in the MAS or other diagnoses patients. This finding is in line with findings from other studies. 
While infants with MAS have normal lung development, CDH is associated with lung hypoplasia and 
PPHN. The severity of lung hypoplasia and PPHN in CDH patients covers a wide range. ECMO-
treated CDH patients are regarded as the most severe cases [20, 26]. Their improved survival might 
be counterbalanced by increased morbidity. Maldevelopment of the alveoli and pulmonary vessels 
with disturbed lung growth may be responsible for the deterioration of lung function. Also, prolonged 
ventilatory support and supplemental oxygen after ECMO treatment may result in CLD. Recurrent 
respiratory tract infections can further compromise lung function over time.   
Our group has recently reported a significant decline of exercise capacity in a cohort of ECMO 
survivors which overlaps with the population described in the present study. [28]. Interestingly, this 
decline was irrespective of the underlying diagnosis and we were unable to show an association 
between maximal exercise capacity and SDS of FEV1 and FEV1/FVC. For all patients, we advocate an 
active lifestyle and healthy eating pattern as sports participation interacts positively and BMI negatively 
with exercise capacity [29].   
Adequate treatment of recurrent respiratory tract infections, close monitoring and treatment of asthma 
could perhaps halt deterioration of exercise capacity and lung function, especially in CDH patients. 
The use of prophylactic bronchodilators, e.g. during exercise, should not be advised routinely. 
 
From our results it can be concluded that lung function is compromised after neonatal ECMO 
treatment and seems to deteriorate over time in CDH patients only. Airway patency in patients with all 
other diagnoses was within the normal range and remained stable over time. Therefore we assume 
that the underlying condition and not ECMO itself is responsible for the compromised lung function 
post-ECMO. ECMO may even reduce the harmful effects of high pressure ventilation and high doses 
of oxygen. Although the severity of pulmonary hypertension diminishes during ECMO and later in CDH 
patients, sequelae of abnormal lung development will still be present as reflected by compromised 
lung function in this patient group. 
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We recommend prolonged follow-up, especially of patients with CDH, to further elucidate the 
increased respiratory morbidity that occurs with better survival and changing treatment protocols. 
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TABLES 
 
Table 1. Clinical perinatal characteristics of neonatal ECMO-treated patients 
 
 
       All  MAS CDH Other 
 participants    
N (male) 121 (65) 70 (33) 20 (15) 31 (17) 
Gestational age (wk) 40 (34.7-43.3) 40.6 (36.6-43.3) 39 (36-40.9) 38.5 (34.7-42.3) 
Birth weight (g) 3380 (2160-4980) 3400 (2300-4980) 3500 (2160-3810) 3280 (2375-4880) 
Age at onset ECMO (hours) 25 (5-168) 23 (6-73) 16 (5-168) 40 (15-152) 
Duration of ECMO (hours) 132 (24-369) 126 (24-345) 192 (68-369) 122 (53-288) 
Duration of ventilation (days) 10 (1-70) 10 (1-34) 28 (11-70) 9.5 (2-30) 
Highest MAP prior to ECMO 
(cm H2O)  
20 (12-45) 20 (14-30) 19 (12-45) 19 (13-26) 
Highest OI prior to ECMO,  43 (15-143) 44 (27-143) 44 (15-130) 40 (21-106) 
NO treated newborns, n (%) 80 (66) 42 (60) 13 (65) 25 (81) 
CLD, n (%) 22 (18.2) 12 (17.2) 10 (50.0) - 
    Mild CLD 11 (9.1) 10 (14.3) 1 (5.0) - 
    Moderate CLD 1 (0.8) - 1 (5.0) - 
    Severe CLD 10 (8.3) 2 (2.9) 8 (40.0) - 
 
Data are expressed as median (range) unless otherwise indicated. Shown are the total group and the 
subgroups of infants. ECMO: Extracorporeal membrane oxygenation. MAS: meconium aspiration 
syndrome. CDH: congenital diaphragmatic hernia. MAP: mean airway pressure. OI: oxygenation 
index. NO= nitric oxide therapy. CLD: chronic lung disease, classified according to Jobe and Bancalari 
[13] 
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Table 2: Longitudinal results of spirometry after neonatal ECMO, after bronchodilation. 
 
     5 yrs (n=72)  8 yrs (n=77)  12 yrs (n=42)
  
 
SDS FEV1 All participants   0.07 (0.14)  -0.40 (0.15)†  -0.52 (0.16)† 
  MAS    0.49 (0.17)‡   0.12 (0.14)   0.01 (0.23) 
  CDH   -0.71 (0.40)  -2.27 (0.36)*  -2.73 (0.61)† 
  Other    0.01 (0.23)   0.08 (0.31)  -0.49 (0.25) 
SDS FVC All participants  -0.08 (0.15)  -0.22 (0.13)  -0.29 (0.16) 
  MAS    0.40 (0.18)†   0.01 (0.15)   0.12 (0.27) 
  CDH   -0.69 (0.43)  -1.48 (0.35)*  -1.28 (0.98) 
  Other   -0.01 (0.29)   0.19 (0.25)  -0.17 (0.33) 
SDS FEV1/FVC All participants   0.32 (0.15)  -0.53 (0.12)*  -0.63 (0.15)* 
  MAS    0.22 (0.19)  -0.19 (0.11)  -0.32 (0.19) 
  CDH    0.11 (0.35)  -1.47 (0.39)‡  -2.16 (0.30)‡ 
  Other    0.21 (0.35)  -0.37 (0.28)  -0.61 (0.34) 
SDS FEF25-75 All participants  -0.56 (0.19)‡  -1.02 (0.18)*  -0.97 (0.20)* 
  MAS   -0.12 (0.25)  -0.34 (0.14)†  -0.67 (0.21)‡ 
  CDH   -1.76 (0.42) ‡  -3.07 (0.46)*  -3.28 (0.54)‡ 
  Other   -0.82 (0.38)  -0.71 (0.42)  -0.93 (0.30)† 
 
ECMO: extracorporeal membrane oxygenation. CDH: congenital diaphragmatic hernia. Mean SDS (± 
SE) are shown for FEV1, FVC, FEV1/FVC, and FEF25-75. Number of patients studied in each group: 
MAS: 35, 46 and 26 at 5, 8 and 12 years, CDH: 15, 14 and 5 at 5, 8 and 12 years. other: 22, 17 and 
11 at 5, 8 and 12 years. 
SDS significantly below normal (SDS=0; one-sample Student T-test): †: p < 0.05; ‡: p < 0.01;*: p ≤ 
0.001 
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Table 3. Static lung volumes and diffusion capacity at 8 and 12 years 
 
 8 years  n 12 years n 
     
RV%TLCspiro  22.1 (8.3) 56 21.1 (7.0) 30 
RV%TLCpleth    29.4 (8.2) 40 26.5 (6.8) 25 
FRCpleth/spiro  1.22 (0.22) 50 1.09 (0.11) 28 
VTA, n (%) 32 (64)  13 (46)  
DLCOc (SDS) 0.32 (1.6) 29 -0.28 (1.5) 22 
KCOc (SDS)  -0.95 (1.1)* 22 -0.41 (1.2) 18 
 
 
 
DLCOc: diffusion capacity corrected for Hb. KCOc: diffusion capacity corrected for alveolar volume and 
Hb. 
RV%TLCspiro, RV%TLCpleth: mean (SD) %. FRCpleth/spiro, Diffusion capacity: mean (SD).  
VTA: volume trapped air; number (%) of patients with significant VTA (defined as FRCpleth/spiro > 1.10) 
is shown.   
*: significantly below normal (SDS-score = 0) (p<0.001 at 8 years).  
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FIGURE LEGENDS 
 
Figure 1: Flowchart: children included in follow-up program. 
 
 
Figure 2. SDS FEV1 (mean, 95%CI) before bronchodilation at 5, 8 and 12 years for the different 
subgroups. Triangles represent CDH patients (n = 14, 13 and 5 at 5, 8, and 12 years respectively); 
circles represent children with MAS (n = 34, 46, and 24 at 5, 8, and 12 years respectively), squares 
represent children who underwent neonatal ECMO for other diagnoses (n = 22, 16 and 9 at 5, 8, and 
12 years respectively). A summary of all cases is shown as diamond. 
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Figure 3. SDS FEV1 (mean, 95%CI) after bronchodilation at 5, 8 and 12 years for the different 
subgroups. Triangles represent CDH patients (n= 10, 14 and 5 at 5, 8, and 12 years respectively); 
circles represent children with MAS (n=26, 46 and 23 at 5, 8, and 12 years respectively), squares 
represent children who underwent neonatal ECMO for other diagnoses (n= 16, 15 and 11 at 5, 8, and 
12 years respectively). A summary of all cases is shown as diamond.  
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Figure 4. Change of SDS FEV1 before bronchodilation in CDH patients from 5 to 12 years. Each dot 
respresents a measurement of an individual patient. 
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Figure 5. Change of SDS FEV1 after bronchodilation in CDH patients from 5 to 12 years. Each dot 
respresents a measurement of an individual patient. 
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